Tier | Contract Status | KOL Type | Image | KOL Name | Institution | Specialty | Asset Assignment | Focus Areas | KOL Source | Engagement Strategy | Relationship Owner (POC) | Relationship Delegate (POC backup) | Last Contacted | Days Since Last Contact | Interaction Count | Follow-Up Actions | ||||
Collaboration powered by Smartsheet | Report Abuse | ||||||||||||||||||||
1 | 🟢 Tier 1 | 📊 Active | 🏥Clinical |
| CHOP | 🧠 Neurology | 🧬💪 Asset 1 | Clinical Trials Gene Therapy Research Neuromuscular Diseases Nonsense Mutations | 🤝Direct Outreach | AdBoard Participation Educational Programs PI Collaboration Patient Support Partnerships Storyboard Development | Sophie Seekwright | Ken Gathermore | 05/15/24 | 370 | 4 | 1 | ||||
2 | 🟢 Tier 1 | 📊 Active | 🏥Clinical |
| University of Pennsylvania | 🧬 Clinical Genetics | 🧬🔬 Asset 3 | Clinical Trials Gene Therapy Patient Safety Evaluations Safety Endpoints | 🏛️ Scientific Congress | AdBoard Participation PI Collaboration | Ken Gathermore | Ella Intellect | 05/20/24 | 365 | 2 | 1 | ||||
3 | 🟡 Tier 2 | 🚫Terminated | 🏥Clinical |
| University of Pennsylvania | 🧠 Neurology | 🧬💪 Asset 1 | Musular Dystrophy Patient Recruitment | 🤝Direct Outreach | PI Collaboration | Sophie Seekwright | Ken Gathermore | 05/15/23 | 736 | 1 | 1 | ||||
4 | 🟡 Tier 2 | 📊 Active | 🏥Clinical |
| MIT | 🧬 Clinical Genetics | 🧬🔬 Asset 3 | Clinical Trials Gene Therapy Research Pediatric Genetic Diseases | 🤝Direct Outreach | AdBoard Participation PI Collaboration | Ella Intellect | Sophie Seekwright | 05/24/24 | 361 | 2 | 1 | ||||
5 | 🟡 Tier 2 | 📊 Active | 🏥Clinical |
| UCSF Department of Ophthalmology | 👁️ Ophthalmology | 🧬👁️Asset 2 | Clinical Trials Gene Therapy Research Macular Degeneration | 👥 KOL Referral | PI Collaboration | Sophie Seekwright | Ken Gathermore | 01/30/23 | 841 | 1 | 1 | ||||
6 | 🟡 Tier 2 | 📊 Active | 🎓 Academic |
| Medical College of Wisconsin | 🐁 Nonclinical Research | 🧬👁️Asset 2 🧬💪 Asset 1 🧬🔬 Asset 3 | Autopsy Histopathology Mitochondial Dysfunction Muscle Disorders Tissue Analysis | 🤝Direct Outreach | AdBoard Participation | Sophie Seekwright | Ken Gathermore | 04/24/24 | 391 | 3 | 1 | ||||
7 | 🟡 Tier 2 | 📊 Active | 🎓 Academic |
| University of Texas | 🧪 Biochemistry | General/NA | AAV Genetic Research Non-GMP Manufacturing | 🤝Direct Outreach | AdBoard Participation | Ken Gathermore | Ella Intellect | 05/11/24 | 374 | 2 | 1 | ||||
8 | 🟢 Tier 1 | 📊 Active | 🏥Clinical |
| Stanford University | 🧬 Clinical Genetics | 🧬🔬 Asset 3 | Clinical Trial Execution Pediatric Genetic Diseases | 🏛️ Scientific Congress | Educational Workshops PI Collaboration | Ken Gathermore | Ella Intellect | 05/13/24 | 372 | 2 | 1 | ||||
9 | 🟡 Tier 2 | 📊 Active | 🏢 Industry |
| BioMrKr LLC | 🧪 Biochemistry | 🧬👁️Asset 2 🧬💪 Asset 1 🧬🔬 Asset 3 | Biomarker Research Clinical Trial Strategy | 🏛️ Scientific Congress | AdBoard Participation | Ella Intellect | Sophie Seekwright | 0 | 0 | ||||||
10 | 🟢 Tier 1 | 📊 Active | 🏥Clinical |
| University of Pennsylvania | 🐁 Nonclinical Research | 🧬💪 Asset 1 | Bioavailability GLP-Studies Nonclinical Submission Data Toxicology Studies | 🤝Direct Outreach | AdBoard Participation Storyboard Development | Ken Gathermore | Ella Intellect | 07/17/24 | 307 | 2 | 1 | ||||
11 | 🟡 Tier 2 | 📊 Active | 👩👨👦Patient Advocacy |
| RareAllies | 🛡️Patient Advocacy | 🧬💪 Asset 1 | Community Outreach Market Access Patient Advocacy Patient Education | 👥 KOL Referral | AdBoard Participation Educational Programs Patient Support Partnerships | Ella Intellect | Sophie Seekwright | 04/05/23 | 776 | 1 | 1 | ||||
12 | 🟠 Tier 3 | 📊 Active | 🎓 Academic |
| University of Chicago | 🧬 Clinical Genetics | General/NA | Cellular Signaling Clinical Protocol Endpoints Molecular Diagnostics Process Improvements | 📡Social Listening | Collaborative Research | Ken Gathermore | Ella Intellect | 01/22/23 | 849 | 1 | 1 | ||||
13 | 🟡 Tier 2 | 📊 Active | 🏢 Industry |
| Harvard Medical School | 🌐 Bioinformatics | 🎯 Targeted Genetic Disorders | 🤝Direct Outreach | Advisory Board Participation | Ken Gathermore | 04/22/23 | 759 | 1 | 1 | ||||||
14 | 🟠 Tier 3 | 📊 Active | 🎓 Academic |
| University of Pennsylvania | 👁️ Ophthalmology | 🧬🔬 Asset 3 | Macular Degeneration | 👥 KOL Referral | Collaborative Research | Ken Gathermore | Ella Intellect | 02/17/23 | 823 | 1 | 1 | ||||
15 | 🟡 Tier 2 | 📊 Active | 🏢 Industry |
| University of Pennsylvania | 🧬 Clinical Genetics | Regulatory Compliance | 🤝Direct Outreach | Educational Programs Storyboard Development | Ken Gathermore | Ella Intellect | 05/10/23 | 741 | 0 | 1 | |||||
16 | 🟢 Tier 1 | 📊 Active | 🏛️ Regulatory |
| RegExPert | ⚖️ Regulatory Affairs | General/NA | Clinical Protocol Endpoints FDA Regulatory Pathways | 📡Social Listening | AdBoard Participation Storyboard Development | Sophie Seekwright | Ken Gathermore | 0 | 0 | ||||||
17 | 🟡 Tier 2 | ⏳ Pending | 🎓 Academic |
| Harvard Medical School | 🧪 Biochemistry | Biomarker Identification | 🏛️ Scientific Congress | Advisory Board Participation Biomarker Research | Ken Gathermore | Sophie Seekwright | 0 | 0 | |||||||
18 | 🟠 Tier 3 | ⏳ Pending | 🏢 Industry |
| MIT | 🌐 Bioinformatics | General/NA | Artifical Intellligence Big Data Biological Databases and Data Integration Data Integration Machine Learning | 👥 KOL Referral | Educational Programs Patient Support Partnerships | Ken Gathermore | 0 | 0 | |||||||
19 | 🟢 Tier 1 | ⏳ Pending | 🎓 Academic |
| Johns Hopkins University | 🧫 Molecular Genetics | Multi-Center Trial Coordination | 🤝Direct Outreach | AdBoard Participation Educational Programs | Sophie Seekwright | Ken Gathermore | 0 | 0 | |||||||
20 | 🟡 Tier 2 | 🔍 Review | 🏥Clinical |
| University of California, Los Angeles | 🔍 Clinical Research | 🧬👁️Asset 2 | Gene Therapy Innovative Clinical Trial Design Study Design | 👥 KOL Referral | PI Collaboration | Sophie Seekwright | Ken Gathermore | 0 | 0 | ||||||
21 | 🟠 Tier 3 | 📤Sent | 👩👨👦Patient Advocacy |
| Patient Advocacy | 🧬 Clinical Genetics | 🧬🔬 Asset 3 | Patient Consent Processes | 🏛️ Scientific Congress | AdBoard Participation Educational Programs Patient Support Partnerships | Ella Intellect | 0 | 0 | |||||||
22 | 🟢 Tier 1 | 📤Sent | 🏥Clinical |
| Stanford University | 👁️ Ophthalmology | 🧬👁️Asset 2 | Clinical Protocol Endpoints | 🏛️ Scientific Congress | PI Collaboration | Ella Intellect | Sophie Seekwright | 0 | 0 | ||||||
23 | 🟡 Tier 2 | 📤Sent | 🎓 Academic |
| University of California, San Francisco | 🧠 Neurology | 🧬💪 Asset 1 | 🏛️ Scientific Congress | Educational Programs Storyboard Development | Ken Gathermore | Ella Intellect | 0 | 0 | |||||||
24 | 🟢 Tier 1 | 📅 Planned | 🏢 Industry |
| Stanford University | 🌐 Bioinformatics | General/NA | Biological Databases and Data Integration Epidemiology and Population Genetics Machine Learning and Artificial Intelligence Transcriptomics | 🏛️ Scientific Congress | Educational Programs | Ella Intellect | Sophie Seekwright | 0 | 0 | ||||||
25 | 🟢 Tier 1 | 📅 Planned | 🏥Clinical |
| Harvard Medical School | 🔍 Clinical Research | 🧬💪 Asset 1 | Clinical Protocol Endpoints | 🤝Direct Outreach | AdBoard Participation PI Collaboration | Ella Intellect | Sophie Seekwright | 0 | 0 |